Conventional aluminum-based adjuvants predominantly induce Th2-biased humoral immunity but exhibit a limited capacity to elicit Th1-mediated cellular immune responses, particularly tumor antigen-specific cytotoxic CD8<sup>+</sup> T lymphocytes (CTLs), which are essential for effective cancer vaccine performance. Here, CD8A is linked to cancer.